Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
International Journal of Cancer
|
April 30, 2002
Expression of endoglin (CD105) in tumor blood vessels
Ben K Seon
International Journal of Oncology
|
October 4, 2006
Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites
Masanori Tsujie, Shima Uneda, Hilda Tsai, et al.
International Journal of Cancer
|
November 26, 2003
Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells
Xinwei She, Fumihiko Matsuno, Naoko Harada, et al.
International Journal of Cancer
|
May 29, 2014
Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)
Hirofumi Toi, Masanori Tsujie, Yuro Haruta, et al.
Leukemia Research
|
January 17, 2024
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b
Ben K Seon, Morihiro Okazaki, Jill Duzen, et al.
International Journal of Cancer
|
January 29, 2008
Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice
Masanori Tsujie, Tomoko Tsujie, Hirofumi Toi, et al.
International Journal of Cancer
|
June 18, 2009
Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature
Shima Uneda, Hirofumi Toi, Tomoko Tsujie, et al.
Cancer Immunology, Immunotherapy : CII
|
April 28, 2005
Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin
Ken Shiozaki, Naoko Harada, William R Greco, et al.
Current Drug Delivery
|
November 2, 2010
Endoglin-targeted cancer therapy
Ben K Seon, Akinao Haba, Fumihiko Matsuno, et al.
Immunologic Research
|
September 19, 2009
Receptor-targeted anticancer therapy
Ben K Seon, Yuro Haruta, Fumihiko Matsuno, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
International Journal of Cancer
|
April 30, 2002
Expression of endoglin (CD105) in tumor blood vessels
Ben K Seon
International Journal of Oncology
|
October 4, 2006
Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites
Masanori Tsujie, Shima Uneda, Hilda Tsai, et al.
International Journal of Cancer
|
November 26, 2003
Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells
Xinwei She, Fumihiko Matsuno, Naoko Harada, et al.
International Journal of Cancer
|
May 29, 2014
Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)
Hirofumi Toi, Masanori Tsujie, Yuro Haruta, et al.
Leukemia Research
|
January 17, 2024
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b
Ben K Seon, Morihiro Okazaki, Jill Duzen, et al.
International Journal of Cancer
|
January 29, 2008
Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice
Masanori Tsujie, Tomoko Tsujie, Hirofumi Toi, et al.
International Journal of Cancer
|
June 18, 2009
Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature
Shima Uneda, Hirofumi Toi, Tomoko Tsujie, et al.
Cancer Immunology, Immunotherapy : CII
|
April 28, 2005
Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin
Ken Shiozaki, Naoko Harada, William R Greco, et al.
Current Drug Delivery
|
November 2, 2010
Endoglin-targeted cancer therapy
Ben K Seon, Akinao Haba, Fumihiko Matsuno, et al.
Immunologic Research
|
September 19, 2009
Receptor-targeted anticancer therapy
Ben K Seon, Yuro Haruta, Fumihiko Matsuno, et al.
Page
of 2